Atheroma Circulatory System
Conditions
Interventions
Following recruitment, we will arrange for the participant to have two PET scans. The first will take place in the three weeks following their stroke and the second will take place approximately 90 da
Sponsors
Cambridge University Hospitals NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Participant is willing and able to give informed consent for participation in the study. 2. Male or Female, aged 50 years or above. 3. Participants have had an ischaemic stroke or transient ischaemic attack (TIA) in the last 7 days that has been confirmed to be due to atheroma in the carotid artery. 4. Have evidence of carotid territory atheroma of at least 30% in the ipsilateral carotid artery to the infarct that is felt to be causative (using Doppler ultrasound or computed tomography angiography).
Exclusion criteria
Exclusion criteria: 1. The participant has a medical history or clinically relevant abnormality identified on the screening medical examination, vital sign measurement, or clinical laboratory examination that is deemed by the principal investigator and/or designee to make the subject ineligible for inclusion, 2. The participant has had a haemorrhagic stroke. 3. The participant is a woman of childbearing potential. 4. The participant is in atrial fibrillation. 5. The participant has had a previous adverse reaction to minocycline. 6. The participant has a medical condition in which the use of minocycline is cautioned: systemic lupus erythematosus (SLE), liver dysfunction, myasthenia gravis, intracranial hypertension, or lactose intolerance. 7. The participant is taking medication where there is a significant risk of interaction with minocycline: anticoagulants, penicillins, isotretinoin. 8. Planned carotid revascularisation procedure prior to the 12-week re-imaging. 9. The participant has evidence of a complete occlusion of their internal carotid artery on the ipsilateral side to the infarct. 10. The participant has limited life expectancy due to another illness or chronic condition making follow-up difficult (e.g. widespread malignancy). 11. The participant has existing co-morbid medical conditions that would prevent them lying flat in the scanner (e.g. heart failure). 12. The participant has known chronic kidney disease that would preclude contrast use (i.e. excluded if eGFR < 30ml/min/1.73m2). 13. The participant is unable to give informed consent. 14. The participant is already participating in two other research studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Microcalcification activity in the asymptomatic/non-culprit carotid atheroma as measured by NaF MDS TBRmax on PET/CT at baseline and at 90 days 2. Macrocalcification in the aortic arch and carotid arteries as measured by calcium scoring using the Agatston method on non-contrast CT at baseline and at 90 days | — |
Secondary
| Measure | Time frame |
|---|---|
| There are no secondary outcome measures | — |
Countries
England, United Kingdom
Contacts
Public ContactShiv Bhakta
Outcome results
None listed